AJMC Staff

Mann spent $1 billion of his own money to bring Afrezza to market. The Los Angeles Times reported he died in Las Vegas.

What we're reading, February 26, 2016: drug makers are facing pressure to calculate the cost of extending a patient's life; a look at how addiction is viewed and treated in the US; and staving off the symptoms of Alzheimer's disease.

Jason Pierre-Paul of the New York Giants injured his hand in a fireworks accident July 4, 2015, and ESPN's Adam Schefter tweeted a photo of his injured hand on July 8.

What we're reading, February 25, 2016: the government will require proof of eligibility for enrollment in special sign-up periods under the Affordable Care Act (ACA); this year's flu vaccine is more effective; and 6 states are suing the Obama administration over an ACA fee.

What we're reading: drug makers are not reporting complete information about side effects; Johnson & Johnson will pay $72 million to the family of a woman who blamed her ovarian cancer on talcum powder; and Maine and Utah make new attempts at expanding Medicaid.

What we're reading, February 23, 2016: drug spending for CVS health plans slowed from 11.8% to 5%; CDC Director Tom Frieden, MD, MPH, talks Zika virus; and an investigation into the HealthCare.gov launch found widespread mismanagement.

The American Journal of Managed Care's co-editor-in-chief A. Mark Fendrick, MD, director of the University of Michigan Center for Value-Based Insurance Design (VBID), is testifying on how the principles of VBID and clinical nuance can contribute to healthcare reform in the US military health system.

What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.

What we're reading, February 19, 2016: long-term hospice care is weighing on Medicare; both the pope and the World Health Organization suggest women in Zika infected countries have access to contraception; and Texas health official steps down after co-authoring study on Planned Parenthood.

What we're reading, February 18, 2016: one-third of clinical trial results are never published; Sandoz challenges rule for notices of biosimilar launches; and hepatitis C combination drug could reduce treatment to just 4 weeks.

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

What we're reading, February 17, 2016: Pfizer pays to settle Medicaid claims case; needle exchanges will get financial boost with federal funding; and in New Jersey, Chris Christie releases budget that includes steep cuts to hospitals.

What we're reading, February 16, 2016: Affordable Care Act enrollment for 2016 is far below initial estimates; healthcare record hacks increased 11,000% in 2015; and genetic testing hasn't seen wide adoption among consumers.

What we're reading, February 15, 2016: despite cuts to the program, enrollment in Medicare Advantage is up 50% over 5 years; orphan drug designations from the FDA up 22% in 2015; and Zika virus infections on the rise in Puerto Rico.

Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.

What we're reading, February 12, 2016: the former Kentucky governor is looking to block the current governor's plans to dismantle Kynect; Senator Orrin Hatch speaks out against Medicare negotiation of drug prices; and the link between Zika and microcephaly is growing stronger.

What we're reading, February 11, 2016: Plaintiffs lose their case against cigarette manufacturer; the politics behind providing care for those infected with Zika; and of course, prescription drug prices.

What we're reading, February 10, 2016: 2 companies change how consumers purchase medicines online; CMS memo reveals the government is mulling changes to Medicare reimbursement; and Johns Hopkins will transplant HIV-positive organs to HIV-positive recipients.

What we're reading, February 9, 2016: Novartis signs 2 performance-based deals for its new heart drug; 8 states significantly reduced uninsured rates; and the Obama administration will ask for $1.8 billion to prepare to fight the Zika virus.

What we're reading, February 8, 2016: 12.7 million people signed up for Affordable Care Act coverage, but 30 million remain uninsured; HHS plans to continue to encourage Medicaid expansion; and report analyzes the effect of patient-centered medical homes on cost and quality.

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

What we're reading, February 5, 2016: new legislation could expand the use of telehealth under Medicare; Massachusetts finds its physicians only screen for depression half the time; and Martin Shkreli pleads the Fifth during most of his testimony before Congress.

What we're reading, February 4, 2016: President Obama is proposing changes to the widely disliked Cadillac tax; Florida declares a health emergency in 4 counties over Zika virus; and drug makers are pouring money into efforts to improve medication adherence.

What we're reading, February 3, 2016: President Obama is asking Congress for $1.1 billion to combat the opioid abuse epidemic; 7 blockbuster drugs with the potential for more than $1 billion in sales each are expected in 2016; and less than half of infants are vaccinated against the flu.

What we're reading, February 2, 2016: Aetna joins other major insurers raising concerns over the Affordable Care Act's insurance exchanges; Sanofi announces plans to develop a Zika vaccine; and Martin Shkreli expected to testify despite dismissing the subpoena.

What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.

A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.

A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found no clinically meaningful differences, plus tbo-filgrastim saved money.

An infographic that looks at what it means to be a physician leader, based on an interview with Anthony D. Slonim, MD, DrPH, president and chief executive officer for Renown Health.

What we're reading, January 29, 2016: newly approved hepatitis C cure will increase competition; California will vote on a proposition to control the cost of prescription drugs; and a special report details drug shortages and rationing decisions.